[{"orgOrder":0,"company":"Mannkind","sponsor":"NRx Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2021","type":"Partnership","leadProduct":"Aviptadil Acetate","moa":"Adrenergic receptor alpha","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Mannkind","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mannkind \/ NRx Pharmaceuticals","highestDevelopmentStatusID":"9","companyTruncated":"Mannkind \/ NRx Pharmaceuticals"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Aviptadil Acetate","moa":"||Adrenergic receptor alpha","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"National Institutes of Health \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"National Institutes of Health \/ Undisclosed"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Molnupiravir","moa":"antivirals","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"National Institutes of Health \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"National Institutes of Health \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Bedaquiline","moa":"ATP synthase","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Peptilogics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"PLG0206","moa":"Bacterial cell membrane","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Peptilogics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Peptilogics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Peptilogics \/ Undisclosed"},{"orgOrder":0,"company":"Peptilogics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"PLG0206","moa":"Bacterial cell membrane","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Peptilogics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Peptilogics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Peptilogics \/ Undisclosed"},{"orgOrder":0,"company":"Peptilogics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"PLG0206","moa":"Bacterial cell membrane","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Peptilogics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Peptilogics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Peptilogics \/ Undisclosed"},{"orgOrder":0,"company":"Peptilogics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"PLG0206","moa":"Bacterial cell membrane","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Peptilogics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Peptilogics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Peptilogics \/ Undisclosed"},{"orgOrder":0,"company":"Lumen Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"LMN-201","moa":"Bacterial cell wall synthesis","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Lumen Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Lumen Bioscience \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Lumen Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Lumen Bioscience","sponsor":"US Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2023","type":"Funding","leadProduct":"LMN-201","moa":"Bacterial cell wall synthesis","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Lumen Bioscience","amount2":0.02,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.02,"dosageForm":"Capsule","sponsorNew":"Lumen Bioscience \/ US Department of Defense","highestDevelopmentStatusID":"9","companyTruncated":"Lumen Bioscience \/ US Department of Defense"},{"orgOrder":0,"company":"Lumen Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"LMN-201","moa":"Bacterial cell wall synthesis","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Lumen Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Lumen Bioscience \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Lumen Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Lumen Bioscience","sponsor":"Congressionally Directed Medical Research Programs","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"LMN-201","moa":"Bacterial cell wall synthesis","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Lumen Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lumen Bioscience \/ Congressionally Directed Medical Research Programs","highestDevelopmentStatusID":"9","companyTruncated":"Lumen Bioscience \/ Congressionally Directed Medical Research Programs"},{"orgOrder":0,"company":"Lumen Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"LMN-201","moa":"Bacterial cell wall synthesis","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Lumen Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lumen Bioscience \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Lumen Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2019","type":"Inapplicable","leadProduct":"Imipenem","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2017","type":"Inapplicable","leadProduct":"Imipenem","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Zavegepant HCl","moa":"Calcitonin gene-related peptide type 1 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Spray","sponsorNew":"Biohaven Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Biohaven Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Zavegepant HCl","moa":"Calcitonin-gene-related peptide receptor, CALCRL\/RAMP1","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"American Regent","sponsor":"CytoDyn","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Agreement","leadProduct":"Leronlimab","moa":"C-C chemokine receptor type 5","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"American Regent","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"American Regent \/ CytoDyn","highestDevelopmentStatusID":"9","companyTruncated":"American Regent \/ CytoDyn"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"CytoDyn","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Collaboration","leadProduct":"Leronlimab","moa":"C-C chemokine receptor type 5","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Institutes of Health \/ CytoDyn","highestDevelopmentStatusID":"9","companyTruncated":"National Institutes of Health \/ CytoDyn"},{"orgOrder":0,"company":"Oruka Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"rNAPc2","moa":"Coagulation factor VII (F7)","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Oruka Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Oruka Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Oruka Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Oruka Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"rNAPc2","moa":"Coagulation factor VII (F7)","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Oruka Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Oruka Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Oruka Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Oruka Therapeutics","sponsor":"University Medical Center of Johannes Gutenberg University Mainz","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2021","type":"Agreement","leadProduct":"rNAPc2","moa":"Coagulation factor VII (F7)","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Oruka Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Oruka Therapeutics \/ University Medical Center of Johannes Gutenberg University Mainz","highestDevelopmentStatusID":"9","companyTruncated":"Oruka Therapeutics \/ University Medical Center of Johannes Gutenberg University Mainz"},{"orgOrder":0,"company":"Oruka Therapeutics","sponsor":"Colorado Prevention Center","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Recombinant Nematode Anticoagulant Protein c2","moa":"Coagulation factor VII; Tissue factor; Coagulation factor X","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Oruka Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oruka Therapeutics \/ Colorado Prevention Center","highestDevelopmentStatusID":"9","companyTruncated":"Oruka Therapeutics \/ Colorado Prevention Center"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Eculizumab","moa":"Complement C5","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Alexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alexion Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Alexion Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"FibroGen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Pamrevlumab","moa":"Connective tissue growth factor","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"FibroGen","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"FibroGen \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"FibroGen \/ Undisclosed"},{"orgOrder":0,"company":"FibroGen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Pamrevlumab","moa":"Connective tissue growth factor","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"FibroGen","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"FibroGen \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"FibroGen \/ Undisclosed"},{"orgOrder":0,"company":"FibroGen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Pamrevlumab","moa":"Connective tissue growth factor","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"FibroGen","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"FibroGen \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"FibroGen \/ Undisclosed"},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Vidofludimus Calcium","moa":"DHODH","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Immunic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Immunic Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Immunic Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Vidofludimus Calcium","moa":"DHODH","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Immunic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Immunic Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Immunic Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"Roth Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Public Offering","leadProduct":"Vidofludimus Calcium","moa":"DHODH","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Immunic Therapeutics","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.029999999999999999,"dosageForm":"Tablet","sponsorNew":"Immunic Therapeutics \/ Roth Capital Partners","highestDevelopmentStatusID":"9","companyTruncated":"Immunic Therapeutics \/ Roth Capital Partners"},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"European Investment Bank","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Funding","leadProduct":"Vidofludimus Calcium","moa":"||DHODH","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Immunic Therapeutics","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.029999999999999999,"dosageForm":"Tablet","sponsorNew":"Immunic Therapeutics \/ European Investment Bank","highestDevelopmentStatusID":"9","companyTruncated":"Immunic Therapeutics \/ European Investment Bank"},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Vidofludimus Calcium","moa":"||DHODH","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Immunic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Immunic Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Immunic Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Vidofludimus Calcium","moa":"DHODH","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Immunic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Immunic Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Immunic Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Vidofludimus Calcium","moa":"DHODH","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Immunic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Immunic Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Immunic Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Vidofludimus Calcium","moa":"DHODH","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Immunic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Immunic Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Immunic Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"Altium Capital","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Financing","leadProduct":"Vidofludimus Calcium","moa":"DHODH","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Immunic Therapeutics","amount2":0.02,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.02,"dosageForm":"Tablet","sponsorNew":"Immunic Therapeutics \/ Altium Capital","highestDevelopmentStatusID":"9","companyTruncated":"Immunic Therapeutics \/ Altium Capital"},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Vidofludimus Calcium","moa":"DHODH","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Immunic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Immunic Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Immunic Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"University Medical Center Goettingen","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Licensing Agreement","leadProduct":"Vidofludimus Calcium","moa":"||DHODH","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Immunic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Immunic Therapeutics \/ University Medical Center Goettingen","highestDevelopmentStatusID":"9","companyTruncated":"Immunic Therapeutics \/ University Medical Center Goettingen"},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Vidofludimus Calcium","moa":"DHODH","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Immunic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immunic Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Immunic Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Emvododstat","moa":"Dihydroorotate dehydrogenase","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"PTC Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"PTC Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Emvododstat","moa":"Dihydroorotate dehydrogenase","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"PTC Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"PTC Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Emvododstat","moa":"Dihydroorotate dehydrogenase","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"PTC Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"PTC Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Emvododstat","moa":"Dihydroorotate dehydrogenase","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"PTC Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"PTC Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"FGK Clinical Research","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"IMU-838","moa":"Dihydroorotate dehydrogenase","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Immunic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Immunic Therapeutics \/ FGK Clinical Research","highestDevelopmentStatusID":"9","companyTruncated":"Immunic Therapeutics \/ FGK Clinical Research"},{"orgOrder":0,"company":"NeuroBo Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Niclosamide","moa":"DNA","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"NeuroBo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"NeuroBo Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"NeuroBo Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"ANA Therapeutics","sponsor":"NeuroBo Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Acquisition","leadProduct":"Niclosamide","moa":"DNA","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"ANA Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"ANA Therapeutics \/ NeuroBo Pharmaceuticals","highestDevelopmentStatusID":"9","companyTruncated":"ANA Therapeutics \/ NeuroBo Pharmaceuticals"},{"orgOrder":0,"company":"ANA Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Niclosamide","moa":"DNA","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"ANA Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"ANA Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"ANA Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"ANA Therapeutics","sponsor":"Quotient Sciences","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Partnership","leadProduct":"Niclosamide","moa":"DNA","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"ANA Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"ANA Therapeutics \/ Quotient Sciences","highestDevelopmentStatusID":"9","companyTruncated":"ANA Therapeutics \/ Quotient Sciences"},{"orgOrder":0,"company":"NeuroBo Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Niclosamide","moa":"||DNA","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"NeuroBo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"NeuroBo Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"NeuroBo Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"NeuroBo Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Niclosamide","moa":"||DNA","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"NeuroBo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"NeuroBo Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"NeuroBo Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"ANA Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Niclosamide","moa":"DNA","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"ANA Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"ANA Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"ANA Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Arrevus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2015","type":"Inapplicable","leadProduct":"Sodium Fusidate","moa":"Elongation factor G","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Arrevus","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Arrevus \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Arrevus \/ Undisclosed"},{"orgOrder":0,"company":"ObvioHealth","sponsor":"RedHill Biopharma","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Upamostat","moa":"enzyme inhibitors: proteolytic enzyme inhibitors","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"ObvioHealth","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"ObvioHealth \/ RedHill Biopharma","highestDevelopmentStatusID":"9","companyTruncated":"ObvioHealth \/ RedHill Biopharma"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Sisunatovir","moa":"Fusion glycoprotein F0","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Sisunatovir","moa":"Fusion glycoprotein F0","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Powder","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Sisunatovir","moa":"Fusion glycoprotein F0","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Sisunatovir","moa":"Fusion glycoprotein F0","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Sisunatovir","moa":"Fusion glycoprotein F0","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Sisunatovir","moa":"Fusion glycoprotein F0","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Kiniksa Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Mavrilimumab","moa":"Granulocyte-macrophage colony-stimulating factor receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Kiniksa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Kiniksa Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Kiniksa Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Kiniksa Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Mavrilimumab","moa":"Granulocyte-macrophage colony-stimulating factor receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Kiniksa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Kiniksa Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Kiniksa Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Kiniksa Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Mavrilimumab","moa":"Granulocyte-macrophage colony-stimulating factor receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Kiniksa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Kiniksa Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Kiniksa Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Kiniksa Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Mavrilimumab","moa":"Granulocyte-macrophage colony-stimulating factor receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Kiniksa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Kiniksa Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Kiniksa Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"ABT-450\/r","moa":"HCV NS3-4A serine protease","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"Chimerix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Dociparstat Sodium","moa":"heparin derivatives","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Chimerix","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chimerix \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Chimerix \/ Undisclosed"},{"orgOrder":0,"company":"Viriom","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"VM-1500A-LAI","moa":"HIV-1 reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Viriom","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Viriom \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Viriom \/ Undisclosed"},{"orgOrder":0,"company":"Viriom","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"VM-1500A-LAI","moa":"HIV-1 reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Viriom","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Viriom \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Viriom \/ Undisclosed"},{"orgOrder":0,"company":"Viriom","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"VM-1500A-LAI","moa":"HIV-1 reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Viriom","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Viriom \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Viriom \/ Undisclosed"},{"orgOrder":0,"company":"Viriom","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"VM-1500","moa":"Human immunodeficiency virus Reverse transcriptase (HIV RT)","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Viriom","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Viriom \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Viriom \/ Undisclosed"},{"orgOrder":0,"company":"Viriom","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"VM-1500","moa":"Human immunodeficiency virus Reverse transcriptase (HIV RT)","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Viriom","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Viriom \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Viriom \/ Undisclosed"},{"orgOrder":0,"company":"Viriom","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"VM-1500","moa":"Human immunodeficiency virus Reverse transcriptase (HIV RT)","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Viriom","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Viriom \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Viriom \/ Undisclosed"},{"orgOrder":0,"company":"Viriom","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"VM-1500","moa":"Human immunodeficiency virus Reverse transcriptase (HIV RT)","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Viriom","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Viriom \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Viriom \/ Undisclosed"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Atazanavir","moa":"Human immunodeficiency virus type 1 protease","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Gilead Sciences \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Gilead Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Tenofovir Alafenamide","moa":"Human immunodeficiency virus type 1 reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gilead Sciences \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Gilead Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Evelo Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"EDP1815","moa":"IL-6 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Evelo Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Evelo Biosciences \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Evelo Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Evelo Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"EDP1815","moa":"IL-6 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Evelo Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Evelo Biosciences \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Evelo Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Evelo Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"Ambrisentan","moa":"||IL-6 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Evelo Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Evelo Biosciences \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Evelo Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Evelo Biosciences","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Public Offering","leadProduct":"EDP1815","moa":"IL-6 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Evelo Biosciences","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.050000000000000003,"dosageForm":"Capsule","sponsorNew":"Evelo Biosciences \/ Morgan Stanley","highestDevelopmentStatusID":"9","companyTruncated":"Evelo Biosciences \/ Morgan Stanley"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"ChAdOx1 nCoV-19","moa":"Immunostimulant","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Emergent BioSolutions","amount2":0.089999999999999997,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.089999999999999997,"dosageForm":"Injection","sponsorNew":"Emergent BioSolutions \/ AstraZeneca","highestDevelopmentStatusID":"9","companyTruncated":"Emergent BioSolutions \/ AstraZeneca"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2018","type":"Inapplicable","leadProduct":"Interferon Alfa-2B","moa":"Interferon alpha\/beta receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"AN2 Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Epetraborole","moa":"Leucine--tRNA ligase","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"AN2 Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AN2 Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"AN2 Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"AN2 Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Epetraborole","moa":"Leucine--tRNA ligase","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"AN2 Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AN2 Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"AN2 Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"AN2 Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Epetraborole","moa":"Leucine--tRNA ligase","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"AN2 Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AN2 Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"AN2 Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"AN2 Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Epetraborole","moa":"Leucine--tRNA ligase","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"AN2 Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AN2 Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"AN2 Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"AN2 Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Epetraborole","moa":"Leucine--tRNA ligase","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"AN2 Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AN2 Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"AN2 Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Foresee Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"FP-025","moa":"Matrix metalloproteinase-12 (MMP-12)","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Foresee Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Foresee Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Foresee Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Medicinova","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Ibudilast","moa":"Phosphodiesterase 5A | Phosphodiesterase 3A | Phosphodiesterase 4 | Phosphodiesterase 10A","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Medicinova","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Medicinova \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Medicinova \/ Undisclosed"},{"orgOrder":0,"company":"Medicinova","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ibudilast","moa":"Phosphodiesterase 5A | Phosphodiesterase 3A | Phosphodiesterase 4 | Phosphodiesterase 10A","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Medicinova","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Medicinova \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Medicinova \/ Undisclosed"},{"orgOrder":0,"company":"Medicinova","sponsor":"University Health Network","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Agreement","leadProduct":"Ibudilast","moa":"Phosphodiesterase 5A | Phosphodiesterase 3A | Phosphodiesterase 4 | Phosphodiesterase 10A","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Medicinova","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Medicinova \/ University Health Network","highestDevelopmentStatusID":"9","companyTruncated":"Medicinova \/ University Health Network"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Israel Institute for Biological Research","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Recombinant Vesicular Stomatitis Virus Delta G","moa":"SARS-CoV-2 replication","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"NRx Pharmaceuticals \/ Israel Institute for Biological Research","highestDevelopmentStatusID":"9","companyTruncated":"NRx Pharmaceuticals \/ Israel Institute for Biological Research"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Israel Institute for Biological Research","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Recombinant Vesicular Stomatitis Virus Delta G","moa":"SARS-CoV-2 replication","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"NRx Pharmaceuticals \/ Israel Institute for Biological Research","highestDevelopmentStatusID":"9","companyTruncated":"NRx Pharmaceuticals \/ Israel Institute for Biological Research"},{"orgOrder":0,"company":"Abpro","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"ABP 300","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Abpro","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Abpro \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Abpro \/ Undisclosed"},{"orgOrder":0,"company":"Abpro","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"ABP 300","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Abpro","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Abpro \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Abpro \/ Undisclosed"},{"orgOrder":0,"company":"Abpro","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"ABP 300","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Abpro","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Abpro \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Abpro \/ Undisclosed"},{"orgOrder":0,"company":"Akston Biosciences","sponsor":"University Medical Centre Groningen","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"AKS-452","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Akston Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Akston Biosciences \/ University Medical Centre Groningen","highestDevelopmentStatusID":"9","companyTruncated":"Akston Biosciences \/ University Medical Centre Groningen"},{"orgOrder":0,"company":"Akston Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"AKS-452","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Akston Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Akston Biosciences \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Akston Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Akston Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"AKS-452","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Akston Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Akston Biosciences \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Akston Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Akston Biosciences","sponsor":"Stelis Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Termination","leadProduct":"AKS-452","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Akston Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Akston Biosciences \/ Stelis Biopharma","highestDevelopmentStatusID":"9","companyTruncated":"Akston Biosciences \/ Stelis Biopharma"},{"orgOrder":0,"company":"Akston Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"AKS-452","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Akston Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Akston Biosciences \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Akston Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Akston Biosciences","sponsor":"University Medical Center Groningen","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"AKS-452","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Akston Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Akston Biosciences \/ University Medical Center Groningen","highestDevelopmentStatusID":"9","companyTruncated":"Akston Biosciences \/ University Medical Center Groningen"},{"orgOrder":0,"company":"Akston Biosciences","sponsor":"Biolexis","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"AKS-452","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Akston Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Akston Biosciences \/ Biolexis","highestDevelopmentStatusID":"9","companyTruncated":"Akston Biosciences \/ Biolexis"},{"orgOrder":0,"company":"Akston Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"AKS-452","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Akston Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Akston Biosciences \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Akston Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Akston Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"AKS-452","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Akston Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Akston Biosciences \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Akston Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Dynavax Technologies","sponsor":"Biological E","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Agreement","leadProduct":"BECOV2D","moa":"||SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Dynavax Technologies","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Dynavax Technologies \/ Biological E","highestDevelopmentStatusID":"9","companyTruncated":"Dynavax Technologies \/ Biological E"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"BioNTech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"BNT162","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pfizer Inc \/ BioNTech","highestDevelopmentStatusID":"9","companyTruncated":"Pfizer Inc \/ BioNTech"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"UK Governement","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"BNT162","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pfizer Inc \/ UK Governement","highestDevelopmentStatusID":"9","companyTruncated":"Pfizer Inc \/ UK Governement"},{"orgOrder":0,"company":"Xencor","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Licensing Agreement","leadProduct":"C-135-LS","moa":"||SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Xencor","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Xencor \/ Bristol Myers Squibb","highestDevelopmentStatusID":"9","companyTruncated":"Xencor \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"HDT Biotech","sponsor":"Rainier Clinical Research Center | C3 Research Associates","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"HDT-301","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"HDT Biotech","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"HDT Biotech \/ Rainier Clinical Research Center | C3 Research Associates","highestDevelopmentStatusID":"9","companyTruncated":"HDT Biotech \/ Rainier Clinical Research Center | C3 Research Associates"},{"orgOrder":0,"company":"HDT Biotech","sponsor":"Gennova Biopharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"HDT-301","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"HDT Biotech","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"HDT Biotech \/ Gennova Biopharmaceuticals","highestDevelopmentStatusID":"9","companyTruncated":"HDT Biotech \/ Gennova Biopharmaceuticals"},{"orgOrder":0,"company":"HDT Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"HDT-301","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"HDT Biotech","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"HDT Biotech \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"HDT Biotech \/ Undisclosed"},{"orgOrder":0,"company":"HDT Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"HDT-301","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"HDT Biotech","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"HDT Biotech \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"HDT Biotech \/ Undisclosed"},{"orgOrder":0,"company":"HDT Biotech","sponsor":"National Institute Of Allergy And Infectious Diseases.","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Funding","leadProduct":"HDT-301","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"HDT Biotech","amount2":0.01,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"HDT Biotech \/ National Institute Of Allergy And Infectious Diseases.","highestDevelopmentStatusID":"9","companyTruncated":"HDT Biotech \/ National Institute Of Allergy And Infectious Diseases."},{"orgOrder":0,"company":"HDT Biotech","sponsor":"Zoic Capital","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Financing","leadProduct":"HDT-301","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"HDT Biotech","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"HDT Biotech \/ Zoic Capital","highestDevelopmentStatusID":"9","companyTruncated":"HDT Biotech \/ Zoic Capital"},{"orgOrder":0,"company":"HDT Biotech","sponsor":"Quratis Co., Ltd","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Agreement","leadProduct":"HDT-301","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"HDT Biotech","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"HDT Biotech \/ Quratis Co., Ltd","highestDevelopmentStatusID":"9","companyTruncated":"HDT Biotech \/ Quratis Co., Ltd"},{"orgOrder":0,"company":"HDT Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"HDT-301","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"HDT Biotech","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"HDT Biotech \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"HDT Biotech \/ Undisclosed"},{"orgOrder":0,"company":"HDT Biotech","sponsor":"Quratis Co., Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"HDT-301","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"HDT Biotech","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"HDT Biotech \/ Quratis Co., Ltd","highestDevelopmentStatusID":"9","companyTruncated":"HDT Biotech \/ Quratis Co., Ltd"},{"orgOrder":0,"company":"HDT Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"HDT-301","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"HDT Biotech","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"HDT Biotech \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"HDT Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Beijing Advaccine Biotechnology","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"INO-4800","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Inovio Pharmaceuticals \/ Beijing Advaccine Biotechnology","highestDevelopmentStatusID":"9","companyTruncated":"Inovio Pharmaceuticals \/ Beijing Advaccine Biotechnology"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Coalition for Epidemic Preparedness Innovations","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"INO-4800","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Inovio Pharmaceuticals \/ Coalition for Epidemic Preparedness Innovations","highestDevelopmentStatusID":"9","companyTruncated":"Inovio Pharmaceuticals \/ Coalition for Epidemic Preparedness Innovations"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"INO-4800","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Inovio Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Inovio Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"INO-4800","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Inovio Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Inovio Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"INO-4800","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Inovio Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Inovio Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"INO-4800","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Inovio Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Inovio Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"INO-4800","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Inovio Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Inovio Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"INO-4800","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Inovio Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Inovio Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"INO-4800","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Inovio Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Inovio Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Richter-Helm BioLogics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Partnership","leadProduct":"INO-4800","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Inovio Pharmaceuticals \/ Richter-Helm BioLogics","highestDevelopmentStatusID":"9","companyTruncated":"Inovio Pharmaceuticals \/ Richter-Helm BioLogics"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"The International Vaccine Institute","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Partnership","leadProduct":"INO-4800","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Inovio Pharmaceuticals \/ The International Vaccine Institute","highestDevelopmentStatusID":"9","companyTruncated":"Inovio Pharmaceuticals \/ The International Vaccine Institute"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Funding","leadProduct":"INO-4800","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Inovio Pharmaceuticals","amount2":0.01,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Inovio Pharmaceuticals \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"9","companyTruncated":"Inovio Pharmaceuticals \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Public Offering","leadProduct":"INO-4800","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Inovio Pharmaceuticals","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.050000000000000003,"dosageForm":"Injection","sponsorNew":"Inovio Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Inovio Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"INO-4800","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Inovio Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Inovio Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"INO-4800","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Inovio Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Inovio Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"INO-4800","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Inovio Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Inovio Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"US Department of Defense","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"INO-4800","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Inovio Pharmaceuticals \/ US Department of Defense","highestDevelopmentStatusID":"9","companyTruncated":"Inovio Pharmaceuticals \/ US Department of Defense"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"CEPI","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Funding","leadProduct":"INO-4800","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Inovio Pharmaceuticals","amount2":0.01,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Inovio Pharmaceuticals \/ CEPI","highestDevelopmentStatusID":"9","companyTruncated":"Inovio Pharmaceuticals \/ CEPI"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"CEPI","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Funding","leadProduct":"INO-4800","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Inovio Pharmaceuticals","amount2":0.02,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Inovio Pharmaceuticals \/ CEPI","highestDevelopmentStatusID":"9","companyTruncated":"Inovio Pharmaceuticals \/ CEPI"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"INO-4800","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Inovio Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Inovio Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"INO-4800","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Inovio Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Inovio Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"INO-4800","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Inovio Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Inovio Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"INO-4800","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Inovio Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Inovio Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Coalition for Epidemic Preparedness Innovations","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Funding","leadProduct":"INO-4800","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Inovio Pharmaceuticals","amount2":0.01,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Inovio Pharmaceuticals \/ Coalition for Epidemic Preparedness Innovations","highestDevelopmentStatusID":"9","companyTruncated":"Inovio Pharmaceuticals \/ Coalition for Epidemic Preparedness Innovations"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Beijing Advaccine Biotechnology","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"INO-4800","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Inovio Pharmaceuticals \/ Beijing Advaccine Biotechnology","highestDevelopmentStatusID":"9","companyTruncated":"Inovio Pharmaceuticals \/ Beijing Advaccine Biotechnology"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Coalition for Epidemic Preparedness Innovations","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"INO-4800","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Inovio Pharmaceuticals \/ Coalition for Epidemic Preparedness Innovations","highestDevelopmentStatusID":"9","companyTruncated":"Inovio Pharmaceuticals \/ Coalition for Epidemic Preparedness Innovations"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"INO-4800","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Inovio Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Inovio Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"mRNA-1273.211","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Moderna Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Moderna Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"mRNA-1273.211","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Moderna Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Moderna Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"ImmunityBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"hAd5-S-Fusion","moa":"SARS-CoV-2 Spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"ImmunityBio","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Liquid","sponsorNew":"ImmunityBio \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"ImmunityBio \/ Undisclosed"},{"orgOrder":0,"company":"ImmunityBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"hAd5-S-Fusion","moa":"SARS-CoV-2 Spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"ImmunityBio","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"ImmunityBio \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"ImmunityBio \/ Undisclosed"},{"orgOrder":0,"company":"Dynavax Technologies","sponsor":"Clover Biopharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Agreement","leadProduct":"5QB0T2IUN0","moa":"||SARS-CoV-2 S-trimer","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Dynavax Technologies","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Dynavax Technologies \/ Clover Biopharmaceuticals","highestDevelopmentStatusID":"9","companyTruncated":"Dynavax Technologies \/ Clover Biopharmaceuticals"},{"orgOrder":0,"company":"Ansun Biopharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Sialidase L","moa":"Sialic acid receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Ansun Biopharm","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Ansun Biopharm \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Ansun Biopharm \/ Undisclosed"},{"orgOrder":0,"company":"Ansun Biopharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Sialidase L","moa":"Sialic acid receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Ansun Biopharm","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Ansun Biopharm \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Ansun Biopharm \/ Undisclosed"},{"orgOrder":0,"company":"Ansun Biopharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"DAS181","moa":"Sialoglycans | Glycosaminoglycans","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Ansun Biopharm","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ansun Biopharm \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Ansun Biopharm \/ Undisclosed"},{"orgOrder":0,"company":"Invivyd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"ADG20","moa":"Spike glycoprotein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Invivyd","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Invivyd \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Invivyd \/ Undisclosed"},{"orgOrder":0,"company":"Invivyd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"ADG20","moa":"Spike glycoprotein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Invivyd","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Invivyd \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Invivyd \/ Undisclosed"},{"orgOrder":0,"company":"Invivyd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Adintrevimab","moa":"Spike glycoprotein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Invivyd","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Invivyd \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Invivyd \/ Undisclosed"},{"orgOrder":0,"company":"Invivyd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Adintrevimab","moa":"Spike glycoprotein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Invivyd","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Invivyd \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Invivyd \/ Undisclosed"},{"orgOrder":0,"company":"Invivyd","sponsor":"Google Ventures","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Series B Financing","leadProduct":"Adintrevimab","moa":"Spike glycoprotein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Invivyd","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.080000000000000002,"dosageForm":"Injection","sponsorNew":"Invivyd \/ Google Ventures","highestDevelopmentStatusID":"9","companyTruncated":"Invivyd \/ Google Ventures"},{"orgOrder":0,"company":"Invivyd","sponsor":"Biocon","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Partnership","leadProduct":"Adintrevimab","moa":"Spike glycoprotein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Invivyd","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Invivyd \/ Biocon","highestDevelopmentStatusID":"9","companyTruncated":"Invivyd \/ Biocon"},{"orgOrder":0,"company":"Invivyd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Adintrevimab","moa":"Spike glycoprotein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Invivyd","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Invivyd \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Invivyd \/ Undisclosed"},{"orgOrder":0,"company":"Invivyd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Adintrevimab","moa":"Spike glycoprotein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Invivyd","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Invivyd \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Invivyd \/ Undisclosed"},{"orgOrder":0,"company":"Invivyd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Adintrevimab","moa":"Spike glycoprotein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Invivyd","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Invivyd \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Invivyd \/ Undisclosed"},{"orgOrder":0,"company":"Invivyd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Adintrevimab","moa":"Spike glycoprotein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Invivyd","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Invivyd \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Invivyd \/ Undisclosed"},{"orgOrder":0,"company":"Invivyd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Adintrevimab","moa":"Spike glycoprotein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Invivyd","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Invivyd \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Invivyd \/ Undisclosed"},{"orgOrder":0,"company":"Invivyd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Adintrevimab","moa":"Spike glycoprotein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Invivyd","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Invivyd \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Invivyd \/ Undisclosed"},{"orgOrder":0,"company":"Invivyd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Adintrevimab","moa":"Spike glycoprotein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Invivyd","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Invivyd \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Invivyd \/ Undisclosed"},{"orgOrder":0,"company":"Invivyd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Adintrevimab","moa":"Spike glycoprotein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Invivyd","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Invivyd \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Invivyd \/ Undisclosed"},{"orgOrder":0,"company":"Invivyd","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Series C Financing","leadProduct":"Adintrevimab","moa":"Spike glycoprotein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Invivyd","amount2":0.34000000000000002,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.34000000000000002,"dosageForm":"Injection","sponsorNew":"Invivyd \/ RA Capital Management","highestDevelopmentStatusID":"9","companyTruncated":"Invivyd \/ RA Capital Management"},{"orgOrder":0,"company":"National Institute of Allergy and Infectious Diseases","sponsor":"Eli Lilly | Advancing Clinical Therapeutics Globally | Brii Biosciences | AstraZeneca | Sagent Pharmaceuticals | Synairgen | Bristol Myers Squibb | SAB Biotherapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Bamlanivimab","moa":"Spike glycoprotein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"National Institute of Allergy and Infectious Diseases","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"National Institute of Allergy and Infectious Diseases \/ Eli Lilly | Advancing Clinical Therapeutics Globally | Brii Biosciences | AstraZeneca | Sagent Pharmaceuticals | Synairgen | Bristol Myers Squibb | SAB Biotherapeutics","highestDevelopmentStatusID":"9","companyTruncated":"National Institute of Allergy and Infectious Diseases \/ Eli Lilly | Advancing Clinical Therapeutics Globally | Brii Biosciences | AstraZeneca | Sagent Pharmaceuticals | Synairgen | Bristol Myers Squibb | SAB Biotherapeutics"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"AbCellera","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Bamlanivimab","moa":"||Spike glycoprotein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Regeneron Pharmaceuticals \/ AbCellera","highestDevelopmentStatusID":"9","companyTruncated":"Regeneron Pharmaceuticals \/ AbCellera"},{"orgOrder":0,"company":"Vir Biotechnology","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"VIR-7831","moa":"Spike glycoprotein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Vir Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Vir Biotechnology \/ GSK","highestDevelopmentStatusID":"9","companyTruncated":"Vir Biotechnology \/ GSK"},{"orgOrder":0,"company":"Vir Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"VIR-7831","moa":"Spike glycoprotein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Vir Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Vir Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Vir Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"Vir Biotechnology","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"VIR-7831","moa":"Spike glycoprotein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Vir Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Vir Biotechnology \/ GSK","highestDevelopmentStatusID":"9","companyTruncated":"Vir Biotechnology \/ GSK"},{"orgOrder":0,"company":"Vir Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"VIR-7831","moa":"Spike glycoprotein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Vir Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Vir Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Vir Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"Adamis Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Tempol","moa":"Superoxide dismutase Cu-Zn (SOD Cu-Zn)","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Adamis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Adamis Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Adamis Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Adamis Pharmaceuticals","sponsor":"Human Immune Monitoring Center at Stanford University","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tempol","moa":"Superoxide dismutase Cu-Zn (SOD Cu-Zn)","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Adamis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Adamis Pharmaceuticals \/ Human Immune Monitoring Center at Stanford University","highestDevelopmentStatusID":"9","companyTruncated":"Adamis Pharmaceuticals \/ Human Immune Monitoring Center at Stanford University"},{"orgOrder":0,"company":"Adamis Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tempol","moa":"Superoxide dismutase Cu-Zn (SOD Cu-Zn)","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Adamis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Adamis Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Adamis Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Adamis Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Tempol","moa":"Superoxide dismutase Cu-Zn (SOD Cu-Zn)","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Adamis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Adamis Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Adamis Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Adamis Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tempol","moa":"Superoxide dismutase Cu-Zn (SOD Cu-Zn)","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Adamis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Adamis Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Adamis Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Adamis Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tempol","moa":"Superoxide dismutase Cu-Zn (SOD Cu-Zn)","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Adamis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Adamis Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Adamis Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Adamis Pharmaceuticals","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Tempol","moa":"Superoxide dismutase Cu-Zn (SOD Cu-Zn)","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Adamis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Adamis Pharmaceuticals \/ National Institutes of Health","highestDevelopmentStatusID":"9","companyTruncated":"Adamis Pharmaceuticals \/ National Institutes of Health"},{"orgOrder":0,"company":"Adamis Pharmaceuticals","sponsor":"Stanford University","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tempol","moa":"Superoxide dismutase Cu-Zn (SOD Cu-Zn)","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Adamis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Adamis Pharmaceuticals \/ Stanford University","highestDevelopmentStatusID":"9","companyTruncated":"Adamis Pharmaceuticals \/ Stanford University"},{"orgOrder":0,"company":"Adamis Pharmaceuticals","sponsor":"Galveston National Laboratory","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tempol","moa":"Superoxide dismutase Cu-Zn (SOD Cu-Zn)","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Adamis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Adamis Pharmaceuticals \/ Galveston National Laboratory","highestDevelopmentStatusID":"9","companyTruncated":"Adamis Pharmaceuticals \/ Galveston National Laboratory"},{"orgOrder":0,"company":"Adamis Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tempol","moa":"Superoxide dismutase Cu-Zn (SOD Cu-Zn)","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Adamis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Adamis Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Adamis Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Adamis Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tempol","moa":"Superoxide dismutase Cu-Zn (SOD Cu-Zn)","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Adamis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Adamis Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Adamis Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Adamis Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Tempol","moa":"Superoxide dismutase Cu-Zn (SOD Cu-Zn)","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Adamis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Adamis Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Adamis Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Adamis Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tempol","moa":"Superoxide dismutase Cu-Zn (SOD Cu-Zn)","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Adamis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Adamis Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Adamis Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Adamis Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Tempol","moa":"Superoxide dismutase Cu-Zn (SOD Cu-Zn)","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Adamis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Adamis Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Adamis Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Adamis Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Tempol","moa":"Superoxide dismutase Cu-Zn (SOD Cu-Zn)","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Adamis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Adamis Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Adamis Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Kare Biosciences","sponsor":"JSS Medical Research | Biomedical Advanced Research and Development Authority | Open Philanthropy | Charak Laboratories | Charak Foundation | Biolink LifeSciences","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Ramatroban","moa":"Thromboxane A2 receptor | G protein-coupled receptor 44","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Kare Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kare Biosciences \/ JSS Medical Research | Biomedical Advanced Research and Development Authority | Open Philanthropy | Charak Laboratories | Charak Foundation | Biolink LifeSciences","highestDevelopmentStatusID":"9","companyTruncated":"Kare Biosciences \/ JSS Medical Research | Biomedical Advanced Research and Development Authority | Open Philanthropy | Charak Laboratories | Charak Foundation | Biolink LifeSciences"},{"orgOrder":0,"company":"Biolink LifeSciences","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Funding","leadProduct":"Ramatroban","moa":"Thromboxane A2 receptor | G protein-coupled receptor 44","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Biolink LifeSciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biolink LifeSciences \/ BARDA","highestDevelopmentStatusID":"9","companyTruncated":"Biolink LifeSciences \/ BARDA"},{"orgOrder":0,"company":"Oruka Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"AB-201","moa":"Tissue factor","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Oruka Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Oruka Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Oruka Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Oruka Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"AB-201","moa":"Tissue factor","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Oruka Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Oruka Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Oruka Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Oruka Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"AB-201","moa":"Tissue factor","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Oruka Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Oruka Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Oruka Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Oruka Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"AB-201","moa":"Tissue factor","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Oruka Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Oruka Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Oruka Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"INmune Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Pegipanermin","moa":"TNF receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"INmune Bio","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"INmune Bio \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"INmune Bio \/ Undisclosed"},{"orgOrder":0,"company":"INmune Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Pegipanermin","moa":"TNF receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"INmune Bio","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"INmune Bio \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"INmune Bio \/ Undisclosed"},{"orgOrder":0,"company":"IQVIA","sponsor":"Walter And Eliza Hall Institute Of Medical Research","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Collaboration","leadProduct":"Hydroxychloroquine Sulphate","moa":"Toll-like receptor 9 | Toll-like receptor 7 | Ferriprotoporphyrin IX","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IQVIA \/ Walter And Eliza Hall Institute Of Medical Research","highestDevelopmentStatusID":"9","companyTruncated":"IQVIA \/ Walter And Eliza Hall Institute Of Medical Research"},{"orgOrder":0,"company":"INmune Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"INB03","moa":"Tumor necrosis factor (TNF)","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"INmune Bio","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"INmune Bio \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"INmune Bio \/ Undisclosed"},{"orgOrder":0,"company":"AnGes","sponsor":"Japan Agency for Medical Research and Development","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"AG0302-COVID19","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"AnGes","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"AnGes \/ Japan Agency for Medical Research and Development","highestDevelopmentStatusID":"9","companyTruncated":"AnGes \/ Japan Agency for Medical Research and Development"},{"orgOrder":0,"company":"AnGes","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"AG0302-COVID19","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"AnGes","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"AnGes \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"AnGes \/ Undisclosed"},{"orgOrder":0,"company":"AnGes","sponsor":"Japan Agency for Medical Research and Development","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"AG0302-COVID19","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"AnGes","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"AnGes \/ Japan Agency for Medical Research and Development","highestDevelopmentStatusID":"9","companyTruncated":"AnGes \/ Japan Agency for Medical Research and Development"},{"orgOrder":0,"company":"AnGes","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"AG0302-COVID-19","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"AnGes","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"AnGes \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"AnGes \/ Undisclosed"},{"orgOrder":0,"company":"AnGes","sponsor":"Fresh Tracks Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"AG0302-COVID-19","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"AnGes","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"AnGes \/ Fresh Tracks Therapeutics","highestDevelopmentStatusID":"9","companyTruncated":"AnGes \/ Fresh Tracks Therapeutics"},{"orgOrder":0,"company":"National Institute of Allergy and Infectious Diseases","sponsor":"HIV Vaccine Trials Network | Bill & Melinda Gates Foundation | Medical Research Council | Sanofi | GSK","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"Alvac-Hiv","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"National Institute of Allergy and Infectious Diseases","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"National Institute of Allergy and Infectious Diseases \/ HIV Vaccine Trials Network | Bill & Melinda Gates Foundation | Medical Research Council | Sanofi | GSK","highestDevelopmentStatusID":"9","companyTruncated":"National Institute of Allergy and Infectious Diseases \/ HIV Vaccine Trials Network | Bill & Melinda Gates Foundation | Medical Research Council | Sanofi | GSK"},{"orgOrder":0,"company":"National Institute of Allergy and Infectious Diseases","sponsor":"HIV Vaccine Trials Network | Sanofi | GSK","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"Alvac-Hiv","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"National Institute of Allergy and Infectious Diseases","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"National Institute of Allergy and Infectious Diseases \/ HIV Vaccine Trials Network | Sanofi | GSK","highestDevelopmentStatusID":"9","companyTruncated":"National Institute of Allergy and Infectious Diseases \/ HIV Vaccine Trials Network | Sanofi | GSK"},{"orgOrder":0,"company":"National Institute of Allergy and Infectious Diseases","sponsor":"Sanofi | GSK | Bill & Melinda Gates Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"Alvac-Hiv","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"National Institute of Allergy and Infectious Diseases","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"National Institute of Allergy and Infectious Diseases \/ Sanofi | GSK | Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"9","companyTruncated":"National Institute of Allergy and Infectious Diseases \/ Sanofi | GSK | Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"National Institute of Allergy and Infectious Diseases","sponsor":"GSK | Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"Alvac-Hiv","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"National Institute of Allergy and Infectious Diseases","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"National Institute of Allergy and Infectious Diseases \/ GSK | Sanofi","highestDevelopmentStatusID":"9","companyTruncated":"National Institute of Allergy and Infectious Diseases \/ GSK | Sanofi"},{"orgOrder":0,"company":"NovaBay Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"CD07223","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"NovaBay Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NovaBay Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"NovaBay Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Novavax","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"CIC Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Novavax","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novavax \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Novavax \/ Undisclosed"},{"orgOrder":0,"company":"Novavax","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"CIC Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Novavax","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novavax \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Novavax \/ Undisclosed"},{"orgOrder":0,"company":"MICROGEN","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"COVID-globulin","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"MICROGEN","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"MICROGEN \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"MICROGEN \/ Undisclosed"},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"Clinical Research Management","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"EVO100","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Evofem Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Evofem Biosciences \/ Clinical Research Management","highestDevelopmentStatusID":"9","companyTruncated":"Evofem Biosciences \/ Clinical Research Management"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"GS-1720","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gilead Sciences \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Gilead Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"GS-1720","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gilead Sciences \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Gilead Sciences \/ Undisclosed"},{"orgOrder":0,"company":"HilleVax","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"HIL-214","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"HilleVax","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"HilleVax \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"HilleVax \/ Undisclosed"},{"orgOrder":0,"company":"HilleVax","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"HIL-214","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"HilleVax","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"HilleVax \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"HilleVax \/ Undisclosed"},{"orgOrder":0,"company":"HilleVax","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"HIL-214","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"HilleVax","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"HilleVax \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"HilleVax \/ Undisclosed"},{"orgOrder":0,"company":"HilleVax","sponsor":"Frazier Healthcare","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Financing","leadProduct":"HIL-214","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"HilleVax","amount2":0.14000000000000001,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.14000000000000001,"dosageForm":"Injection","sponsorNew":"HilleVax \/ Frazier Healthcare","highestDevelopmentStatusID":"9","companyTruncated":"HilleVax \/ Frazier Healthcare"},{"orgOrder":0,"company":"HilleVax","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"HIL-214","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"HilleVax","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"HilleVax \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"HilleVax \/ Undisclosed"},{"orgOrder":0,"company":"HilleVax","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"HIL-214","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"HilleVax","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"HilleVax \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"HilleVax \/ Undisclosed"},{"orgOrder":0,"company":"HilleVax","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"HIL-214","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"HilleVax","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"HilleVax \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"HilleVax \/ Undisclosed"},{"orgOrder":0,"company":"HilleVax","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Public Offering","leadProduct":"HIL-214","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"HilleVax","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.12,"dosageForm":"Injection","sponsorNew":"HilleVax \/ J.P. Morgan","highestDevelopmentStatusID":"9","companyTruncated":"HilleVax \/ J.P. Morgan"},{"orgOrder":0,"company":"HilleVax","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"HIL-214","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"HilleVax","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"HilleVax \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"HilleVax \/ Undisclosed"},{"orgOrder":0,"company":"HilleVax","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Public Offering","leadProduct":"HIL-214","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"HilleVax","amount2":0.12,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.12,"dosageForm":"Injection","sponsorNew":"HilleVax \/ J.P. Morgan","highestDevelopmentStatusID":"9","companyTruncated":"HilleVax \/ J.P. Morgan"},{"orgOrder":0,"company":"HilleVax","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"HIL-214","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"HilleVax","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HilleVax \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"HilleVax \/ Undisclosed"},{"orgOrder":0,"company":"HilleVax","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"HIL-214","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"HilleVax","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HilleVax \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"HilleVax \/ Undisclosed"},{"orgOrder":0,"company":"HilleVax","sponsor":"XOMA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2025","type":"Acquisition","leadProduct":"HIL-214","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"HilleVax","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"HilleVax \/ XOMA","highestDevelopmentStatusID":"9","companyTruncated":"HilleVax \/ XOMA"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"IIBR-100","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NRx Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"NRx Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Novavax","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"JN.1 Subvariant SARS CoV-2 rS Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Novavax","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novavax \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Novavax \/ Undisclosed"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"mRNA-1273.529","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Moderna Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Moderna Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Athersys","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Public Offering","leadProduct":"MultiStem","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Athersys","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.050000000000000003,"dosageForm":"Undisclosed","sponsorNew":"Athersys \/ BofA Securities","highestDevelopmentStatusID":"9","companyTruncated":"Athersys \/ BofA Securities"},{"orgOrder":0,"company":"Biomed Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"NA-831","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Biomed Industries","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biomed Industries \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Biomed Industries \/ Undisclosed"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Israel Institute for Biological Research","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"rVSV-SARS-CoV-2-S Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"NRx Pharmaceuticals \/ Israel Institute for Biological Research","highestDevelopmentStatusID":"9","companyTruncated":"NRx Pharmaceuticals \/ Israel Institute for Biological Research"},{"orgOrder":0,"company":"Novavax","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"tNIV","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Novavax","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novavax \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Novavax \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"V591","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"V591","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"V591","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"V591","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Novavax","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"XBB.1.5 Booster Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Novavax","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novavax \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Novavax \/ Undisclosed"},{"orgOrder":0,"company":"Nitric Oxide Innovations","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"TURKEY","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Sodium Nitrite","moa":"Vasodilator","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Nitric Oxide Innovations","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nitric Oxide Innovations \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Nitric Oxide Innovations \/ Undisclosed"},{"orgOrder":0,"company":"Peptilogics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"PLG0206","moa":"Bacterial cell membrane","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Peptilogics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Peptilogics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Peptilogics \/ Undisclosed"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
